1 Endocrinology, Department of, Abdominal Centre, Rigshospitalet, The Capital Region of Denmark2 Department of Clinical Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: email@example.com unknown
A Post Hoc Analysis From the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)
A doubling of serum creatinine value, corresponding to a 57% decline in estimated glomerular filtration rate (eGFR), is used frequently as a component of a composite kidney end point in clinical trials in type 2 diabetes. The aim of this study was to determine whether alternative end points defined by smaller declines in eGFR would improve the statistical power of these clinical trials.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation, 2014, Vol 63, Issue 2, p. 244-50